The coenzyme A biosynthetic pathway: A new tool for prodrug bioactivation. 
Prodrugs account for more than 5% of pharmaceuticals approved worldwide.  Over the past decades several prodrug design strategies have been firmly established; however, only a few functional groups remain amenable to this approach.  The aim of this overview is to highlight the use of coenzyme A (CoA) biosynthetic enzymes as a recently explored bioactivation scheme and provide information about its scope of utility.  This emerging tool is likely to have a strong impact on future medicinal and biological studies as it offers promiscuity, orthogonal selectivity, and the capability of assembling exceptionally large molecules.